Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH: Outperformer, Give Credit When Credit Is Due

<< Previous

Bullboard Posts

Next >>

Comment by PitchinPennieson Jun 27, 2023 11:48am

136 Views

Post# 35516414

RE:RE:RE:RE:CPH: Outperformer, Give Credit When Credit Is Due

There's high priced talent in the office? How did I miss this? Last time I looked it was just Craig and the coffee boy and maybe a couple of fart-catchers.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features